Litigation Details for Sanofi-Aventis U.S. LLC v. MSN Pharmaceuticals, Inc. (D. Del. 2020)

« Back to Dashboard

Sanofi-Aventis U.S. LLC v. MSN Pharmaceuticals, Inc. (D. Del. 2020)

Docket		Date Filed	2020-05-14
Court	District Court, D. Delaware	Date Terminated	2020-08-11
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Parties	SANOFI MATURE IP
Patents	10,583,110
Attorneys	Stamatios Stamoulis
Firms	Stamoulis & Weinblatt LLC
Link to Docket	External link to docket

Details for Sanofi-Aventis U.S. LLC v. MSN Pharmaceuticals, Inc. (D. Del. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-05-14				External link to document
2020-05-14	23	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,583,110 B2. (Attachments: …2020 11 August 2020 1:20-cv-00646 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Sanofi-Aventis U.S. LLC v. MSN Pharmaceuticals, Inc. Litigation Summary and Patent Analysis

Last updated: August 3, 2026

Sanofi-Aventis U.S. LLC v. MSN Pharmaceuticals, Inc., No. 1:20-cv-00646, was a Hatch-Waxman patent case filed in the U.S. District Court for the District of Delaware. The dispute concerned MSN's abbreviated new drug application for a generic version of teriflunomide, marketed by Sanofi as Aubagio, a multiple-sclerosis treatment. Sanofi asserted Orange Book-listed patents after receiving MSN's Paragraph IV certification.

The case presented a conventional small-molecule generic-entry dispute. It did not involve biosimilar litigation, patentability of a biologic, or manufacturing-process claims of the type usually associated with complex biologics. The principal commercial issue was whether MSN could launch generic teriflunomide before Sanofi's listed patent protection expired or before a negotiated entry date.

What drug and FDA regulatory pathway were involved?

The product was teriflunomide, the active ingredient in Aubagio tablets.

Item	Detail
Reference drug	Aubagio
Active ingredient	Teriflunomide
Innovator	Sanofi
Dosage form	Oral tablets
Strengths	7 mg and 14 mg
Regulatory pathway	ANDA under the Hatch-Waxman Act
Generic applicant	MSN Pharmaceuticals, Inc.
Litigation court	U.S. District Court for the District of Delaware
Civil action	No. 1:20-cv-00646
Patent-challenge mechanism	Paragraph IV certification

A Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. Filing an ANDA containing a Paragraph IV certification and providing the required notice to the patent holder creates an act of infringement under 35 U.S.C. § 271(e)(2), allowing the brand company to sue before commercial launch (35 U.S.C. § 271(e)(2); 21 U.S.C. § 355(j)(2)(A)(vii)(IV)).

What patents protected Aubagio and what did Sanofi assert?

Sanofi's litigation position centered on patents listed for teriflunomide in the FDA Orange Book. The asserted portfolio was directed principally to teriflunomide compositions and therapeutic use rather than a biosimilar-style package covering a reference biologic, cell line, or manufacturing platform.

The public case record should be read together with the Orange Book entries applicable to Aubagio because the complaint and subsequent docket filings identify the patents placed in dispute, while the Orange Book establishes the regulatory listing and expiration framework (FDA, Approved Drug Products with Therapeutic Equivalence Evaluations).

Patent-estate structure

Sanofi's protection for Aubagio can be divided into four categories:

1. Active-ingredient and composition claims. These claims cover teriflunomide or pharmaceutical compositions containing it.
2. Method-of-use claims. These claims cover treatment of multiple sclerosis and related dosing or administration approaches.
3. Formulation claims. These claims can address tablet composition, excipients, dissolution, stability, or release characteristics.
4. Manufacturing and process claims. These claims cover preparation or purification of teriflunomide and generally create a weaker barrier to an ANDA product if the generic applicant uses a noninfringing process.

The commercial strength of the portfolio depended on which claims were listed for the specific Aubagio strengths and which claims MSN challenged. A generic applicant can avoid a process patent more easily than it can avoid a valid composition patent that reads directly on the active ingredient.

What was the Paragraph IV challenge in this case?

MSN's ANDA certification placed at least one Orange Book-listed Sanofi patent in dispute. Sanofi responded by filing the Delaware action within the statutory 45-day period associated with the Paragraph IV notice. That filing triggered the statutory 30-month stay of FDA approval, subject to statutory exceptions and court action (21 U.S.C. § 355(j)(5)(B)(iii)).

The case therefore had two separate dimensions:

• Regulatory timing: whether FDA approval could become effective during the 30-month stay.
• Patent merits: whether the challenged claims were valid, enforceable, and infringed.

The Paragraph IV framework does not itself establish patent invalidity or infringement. It creates jurisdiction and permits early adjudication. The generic applicant must still prove its invalidity or noninfringement defenses, while the brand must establish infringement of an enforceable claim.

What was the litigation posture and outcome?

The action was part of Sanofi's broader effort to protect Aubagio against ANDA applicants. The docket reflects a Hatch-Waxman dispute rather than a conventional post-launch patent case. The public record does not show a reported trial verdict or a published Delaware merits opinion that invalidated the Aubagio patents in this specific action.

The case's business significance therefore turns less on a judicial claim-construction precedent and more on the timing of generic approval, any negotiated resolution, and the status of the underlying Orange Book patents. A docket disposition without a merits opinion generally does not establish that the asserted patents were valid, invalid, infringed, or unenforceable.

Procedural significance

The case had the following practical features:

• Sanofi used the statutory infringement mechanism to challenge MSN's ANDA before launch.
• The litigation delayed FDA approval during the applicable statutory stay unless the stay expired, was shortened, or was otherwise terminated.
• MSN could continue pursuing FDA review while the patent case proceeded.
• The action did not create a final judicial finding applicable to all other generic applicants.
• Any settlement or dismissal would bind the parties according to its terms but would not automatically determine the rights of unrelated ANDA filers.

When did Aubagio lose exclusivity?

Aubagio's market protection had several separate components:

Protection	Effect
New chemical entity exclusivity	Delayed ANDA filing for the statutory period after approval
Orange Book patents	Created potential approval stay and infringement exposure
Pediatric exclusivity, if applicable	Could add six months to qualifying patent or regulatory protection
Regulatory approval	Did not itself prevent all future generic activity after statutory exclusivity periods ended

Patent expiration must be distinguished from FDA exclusivity. A patent may expire after regulatory exclusivity ends, or regulatory exclusivity may expire while a listed patent remains enforceable. The effective generic-entry date is usually determined by the later of the applicable regulatory restriction, patent-based restriction, settlement terms, and FDA approval requirements.

For teriflunomide, the principal commercial patent barrier extended beyond the earliest regulatory exclusivity period. Generic approval and launch activity therefore depended on the Orange Book patent schedule and the resolution of Paragraph IV litigation involving multiple applicants.

What FDA and Orange Book issues mattered?

FDA's Orange Book listing determined which patents could support a Paragraph IV action and a 30-month stay. The listing did not mean that every patent was necessarily valid or enforceable. It meant that the patent was submitted by the NDA holder for listing in connection with the approved drug and met FDA's listing framework.

Relevant Orange Book issues included:

• Whether the patent was listed against the teriflunomide tablet strengths covered by MSN's ANDA.
• Whether the patent claimed the drug substance, drug product, or method of use.
• Whether MSN submitted a Paragraph IV certification or a section viii statement for method-of-use claims.
• Whether the statutory stay remained in effect when FDA completed technical review.
• Whether any patent expiration date, pediatric extension, or settlement restriction controlled the effective approval date.

A section viii statement would allow an ANDA applicant to carve out a patented method of use from its labeling. A Paragraph IV certification, by contrast, directly contests the patent and exposes the applicant to an infringement action.

How strong was Sanofi's patent estate?

Sanofi's Aubagio estate had moderate strategic value but a declining long-term barrier as the core product patents approached expiration. The strongest claims were those that directly covered teriflunomide or a pharmaceutical composition required by the ANDA. Method-of-use patents were more vulnerable to labeling carve-outs, and process patents were more vulnerable to alternative manufacturing routes.

Strength factors

Sanofi's position was strengthened by:

• Direct association between the asserted patents and the approved teriflunomide product.
• Ability to invoke the Hatch-Waxman statutory stay.
• Multiple potential claim categories, including composition and use claims.
• The cost and delay associated with launching before final resolution.

Weakness factors

The estate was weakened by:

• The limited remaining life of older Aubagio patents.
• The availability of alternative processes and formulations.
• The possibility of a noninfringing label for use claims.
• The ability of generic applicants to challenge obviousness, written description, enablement, and claim scope.
• The absence of a reported merits decision establishing broad precedential strength in this specific case.

For investment and licensing analysis, the key question is not the number of listed patents alone. It is whether at least one enforceable claim blocks the ANDA product as formulated, labeled, and manufactured.

What formulation and manufacturing barriers existed?

Teriflunomide is a small molecule administered in an oral tablet. The technical barrier to generic entry was therefore materially lower than the barrier applicable to an injectable biologic or a complex delivery system.

Formulation patents

A formulation patent could be commercially important if it covered:

• The precise tablet composition;
• A required excipient combination;
• Dissolution characteristics;
• Stability parameters;
• Particle size or polymorphic form;
• A controlled-release or otherwise distinctive delivery profile.

A generic applicant can often avoid a formulation patent by using different excipients or manufacturing conditions, provided the resulting product satisfies FDA equivalence requirements. Formulation claims are strongest when the product's bioequivalence and stability specifications effectively require the claimed formulation.

Manufacturing patents

Manufacturing patents can delay or increase the cost of entry but often do not block the product itself. MSN could potentially use an alternative synthesis or purification route. Sanofi would need to show that the route used for the commercial generic product practices an asserted claim.

The manufacturing barrier was therefore less durable than a composition patent that directly covered teriflunomide in the approved dosage form.

Did biosimilar risk apply to this dispute?

No. Aubagio is a small-molecule drug, and MSN's product was pursued through the ANDA pathway rather than the biosimilar pathway under the Biologics Price Competition and Innovation Act.

Issue	Aubagio dispute
Product type	Small molecule
FDA pathway	ANDA
Patent framework	Hatch-Waxman
Biosimilar application	Not applicable
Interchangeability designation	Not applicable
Primary launch issue	Paragraph IV patent challenge

The absence of biosimilar risk does not mean low commercial risk. Small-molecule generics can enter rapidly after patent and regulatory barriers fall, and multiple approved applicants can create substantial price erosion.

Which companies challenged or competed against Aubagio?

Aubagio faced generic competition from multiple ANDA applicants. The competitive landscape included large generic manufacturers and specialty pharmaceutical companies pursuing teriflunomide approvals. Each applicant's launch date depended on its own certifications, litigation, settlement terms, exclusivity position, and manufacturing readiness.

The MSN case should not be treated as controlling all generic-entry dates. A settlement with MSN would not necessarily establish the entry date for another applicant. Conversely, a favorable ruling against one applicant could affect the broader market only if the decision addressed claims and facts common to other products.

Competitive launch scenarios

Scenario	Commercial effect
Sanofi wins on a blocking composition patent	MSN launch delayed until patent expiry or settlement date
MSN wins on invalidity	FDA approval could become effective subject to remaining patents and regulatory requirements
MSN wins on noninfringement	The specific ANDA may proceed without necessarily invalidating the patent
Settlement with a licensed entry date	Entry occurs on the negotiated date and under negotiated conditions
Patent expiry without a settlement restriction	Multiple generics may launch in a compressed period
First-filer exclusivity held by another applicant	MSN's approval may be delayed by 180-day exclusivity rules

How did the case affect Sanofi's revenue exposure?

Aubagio was a significant multiple-sclerosis product, but the revenue impact of generic entry depended on the number of approved entrants and the timing of the first launch. Sanofi's exposure had four components:

1. Loss of branded volume after generic substitution begins.
2. Price erosion from pharmacy benefit and payer substitution.
3. Reduced ability to maintain price through brand loyalty alone.
4. Possible residual revenue from patients who remain on the branded product or from limited distribution arrangements.

An authorized generic, if used, could moderate revenue loss but would also shift some volume into Sanofi-controlled generic channels. A settlement could optimize entry timing but would generally trade patent uncertainty for a defined erosion date.

What licensing deals or settlement agreements were disclosed?

The public case record does not establish a reported license agreement or settlement term that can be treated as a generally applicable Aubagio entry date for all generic applicants. A dismissal or negotiated resolution in an ANDA case does not by itself disclose:

• The agreed launch date;
• Whether Sanofi granted a license;
• Whether an authorized generic was included;
• Whether MSN received supply rights;
• Whether the agreement contained payment, restrictions, or acceleration provisions.

Any commercial conclusion should therefore distinguish a public docket disposition from the confidential economic terms commonly used in Hatch-Waxman settlements.

What generic-entry risks remain?

The principal risks for MSN were:

• An enforceable Orange Book patent covering the ANDA product;
• A continued 30-month stay;
• Loss of first-filer or shared exclusivity economics;
• FDA deficiencies unrelated to patent validity;
• Manufacturing or bioequivalence delays;
• A settlement restricting launch until a later date;
• Rapid price erosion after entry by several approved competitors.

Sanofi's principal risks were:

• Invalidity based on obviousness or anticipation;
• Noninfringement based on MSN's formulation, label, or manufacturing route;
• A court determination that a method-of-use patent could be carved out;
• Patent expiration before trial or appeal;
• Multiple generic launches reducing the value of settlement leverage.

Key Takeaways

• Sanofi-Aventis U.S. LLC v. MSN Pharmaceuticals, Inc., No. 1:20-cv-00646, was a Delaware Hatch-Waxman case involving MSN's proposed generic teriflunomide product.
• The dispute concerned Aubagio, Sanofi's oral multiple-sclerosis treatment.
• MSN's Paragraph IV certification allowed Sanofi to bring a pre-launch infringement action and triggered the statutory approval stay.
• The case involved small-molecule patent risk, not biosimilar litigation.
• Composition and product patents were more important than process patents because they were harder to avoid through manufacturing changes.
• Method-of-use claims could be vulnerable to a section viii label carve-out.
• The public record does not provide a reported merits judgment establishing broad invalidity or infringement findings in this action.
• Generic-entry timing depended on the Orange Book patent schedule, FDA approval, any applicable exclusivity, and the parties' resolution terms.
• The principal commercial risk was rapid erosion of Aubagio revenue after the first approved generic launch.

FAQs

Was MSN's teriflunomide product an authorized generic?

No public record cited here establishes that MSN's product was an authorized generic. An authorized generic is marketed under the brand sponsor's NDA authority, while MSN's product was pursued through an ANDA.

Did the lawsuit involve Aubagio 7 mg, 14 mg, or both strengths?

The dispute concerned MSN's proposed generic teriflunomide tablets. The applicable strength coverage depends on the ANDA and Orange Book patent listings at issue in the pleadings.

Could MSN launch before every Aubagio patent expired?

Potentially, but only if MSN prevailed on the relevant patents, obtained a license or settlement right, used a noninfringing product and label, or otherwise cleared the statutory and regulatory barriers.

Did Sanofi's Aubagio patents block all teriflunomide generics?

No. Patent rights are claim-specific and applicant-specific. A patent may block one ANDA product while another applicant avoids infringement through a different formulation, label, or manufacturing process.

Is this case useful precedent for future generic multiple-sclerosis litigation?

Its greatest value is procedural and commercial. Without a published merits opinion, it provides limited precedential guidance on claim construction, validity, or infringement. Its importance is greater as an example of Sanofi's Hatch-Waxman strategy for protecting teriflunomide.

References

1. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations (Orange Book). U.S. Department of Health and Human Services.

2. Sanofi-Aventis U.S. LLC v. MSN Pharmaceuticals, Inc., No. 1:20-cv-00646, U.S. District Court for the District of Delaware docket.

3. United States Code. 35 U.S.C. § 271(e)(2). Patent infringement arising from submission of an abbreviated new drug application.

4. United States Code. 21 U.S.C. § 355(j). Abbreviated new drug applications and patent certifications.

5. U.S. Food and Drug Administration. (2024). Aubagio prescribing information. U.S. Department of Health and Human Services.